Mizagliflozin not checked

Vogenx, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
3 in total
Targets
 

What this is

How it works
Makes the kidneys flush extra sugar and salt into the urine. Started as a diabetes drug; now also used for heart and kidney disease.-gliflozin: sodium-glucose co-transporter inhibitors WHO name stem
How it’s given
“10mg mizagliflozin capsules orally administered TID for 28 days”In the company’s words, NCT07760961 on ClinicalTrials.gov
Tested for
Postbariatric Hypoglycemia
Main trialPhase 2
“VGX-001-013 (EMERGE) is a Phase 2b study to evaluate an investigational new drug, mizagliflozin, for safety, tolerability and its ability to prevent low blood sugar in patients with post-bariatric hypoglycemia.”In the company’s words, NCT07760961 on ClinicalTrials.gov

Other drugs for Postbariatric Hypoglycemia

All 9 drugs for Postbariatric Hypoglycemia

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Oct 2027 Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia
Phase 2Completed 17 Feb 2023 Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects
Phase 2Completed 1 May 2024 Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Mizagliflozin

Following is part of Solo: you see every change to Mizagliflozin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in